Cargando…
A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study
BACKGROUND: It is 1 of the standard treatment options for metastasis pancreatic cancer to receive nab-paclitaxel (125 mg/m(2)) plus gemcitabine (1000 mg/m(2)) on days 1, 8 and 15 every 28 days. Some patients showed intolerance and inconvenience to this therapeutic regimen. Thus, we conducted this re...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703471/ https://www.ncbi.nlm.nih.gov/pubmed/36423238 http://dx.doi.org/10.1177/10732748221141233 |
_version_ | 1784839856217653248 |
---|---|
author | Chang, Chen Meng, Lingwei Li, Xiaofen Cheng, Ke Yi, Cheng Peng, Bing Ma, Ji Cao, Dan |
author_facet | Chang, Chen Meng, Lingwei Li, Xiaofen Cheng, Ke Yi, Cheng Peng, Bing Ma, Ji Cao, Dan |
author_sort | Chang, Chen |
collection | PubMed |
description | BACKGROUND: It is 1 of the standard treatment options for metastasis pancreatic cancer to receive nab-paclitaxel (125 mg/m(2)) plus gemcitabine (1000 mg/m(2)) on days 1, 8 and 15 every 28 days. Some patients showed intolerance and inconvenience to this therapeutic regimen. Thus, we conducted this retrospective real-world study to determine the efficacy and tolerability of a modified 21-day nab-paclitaxel plus gemcitabine (nab-P/Gem) regimen for the first-line treatment of locally advanced or metastatic pancreatic cancer. METHODS: Patients with locally advanced and metastatic pancreatic cancer treated with nab-paclitaxel (125 mg/m(2)) plus gemcitabine (1000 mg/m(2)) on days 1 and 8 every 21-day at West China Hospital and Shang Jin Hospital of Sichuan University from Mar 2018 to Dec 2021 were reviewed retrospectively. Clinical characteristics of patients were collected. The progression-free survival, overall survival, objective response rate, disease control rate, and toxicity were evaluated. RESULTS: A total of 113 patients who received the modified regimen of 21-day nab-P/Gem chemotherapy were included. The median overall survival was 9.3 months and the median progression-free survival was 4.4 months. The objective response rate and disease control rate were 18.6% and 56.7%, respectively. The median relative dose intensity for this modified regimen was 65%. The adverse events were mild to moderate, and the most common grade 3 or 4 treatment-related adverse events were neutropenia (21%) and leukopenia (16%). CONCLUSIONS: Our study showed that this modified regimen of 21-day nab-P/Gem for locally advanced and metastatic pancreatic cancer had comparable efficacy and tolerable toxicity. This treatment may provide a considerable option for pancreatic cancer patients who desire a modified schedule. The modified regimen of 21-day nab-P/Gem is also an option worth considering during the coronavirus disease 2019 pandemic for minimizing the number of visits and limiting the risk of exposure. |
format | Online Article Text |
id | pubmed-9703471 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-97034712022-11-29 A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study Chang, Chen Meng, Lingwei Li, Xiaofen Cheng, Ke Yi, Cheng Peng, Bing Ma, Ji Cao, Dan Cancer Control Hope In Despair - New Progress in The Diagnosis and Treatment of Pancreatic Cancer Original Research BACKGROUND: It is 1 of the standard treatment options for metastasis pancreatic cancer to receive nab-paclitaxel (125 mg/m(2)) plus gemcitabine (1000 mg/m(2)) on days 1, 8 and 15 every 28 days. Some patients showed intolerance and inconvenience to this therapeutic regimen. Thus, we conducted this retrospective real-world study to determine the efficacy and tolerability of a modified 21-day nab-paclitaxel plus gemcitabine (nab-P/Gem) regimen for the first-line treatment of locally advanced or metastatic pancreatic cancer. METHODS: Patients with locally advanced and metastatic pancreatic cancer treated with nab-paclitaxel (125 mg/m(2)) plus gemcitabine (1000 mg/m(2)) on days 1 and 8 every 21-day at West China Hospital and Shang Jin Hospital of Sichuan University from Mar 2018 to Dec 2021 were reviewed retrospectively. Clinical characteristics of patients were collected. The progression-free survival, overall survival, objective response rate, disease control rate, and toxicity were evaluated. RESULTS: A total of 113 patients who received the modified regimen of 21-day nab-P/Gem chemotherapy were included. The median overall survival was 9.3 months and the median progression-free survival was 4.4 months. The objective response rate and disease control rate were 18.6% and 56.7%, respectively. The median relative dose intensity for this modified regimen was 65%. The adverse events were mild to moderate, and the most common grade 3 or 4 treatment-related adverse events were neutropenia (21%) and leukopenia (16%). CONCLUSIONS: Our study showed that this modified regimen of 21-day nab-P/Gem for locally advanced and metastatic pancreatic cancer had comparable efficacy and tolerable toxicity. This treatment may provide a considerable option for pancreatic cancer patients who desire a modified schedule. The modified regimen of 21-day nab-P/Gem is also an option worth considering during the coronavirus disease 2019 pandemic for minimizing the number of visits and limiting the risk of exposure. SAGE Publications 2022-11-24 /pmc/articles/PMC9703471/ /pubmed/36423238 http://dx.doi.org/10.1177/10732748221141233 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Hope In Despair - New Progress in The Diagnosis and Treatment of Pancreatic Cancer Original Research Chang, Chen Meng, Lingwei Li, Xiaofen Cheng, Ke Yi, Cheng Peng, Bing Ma, Ji Cao, Dan A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study |
title | A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study |
title_full | A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study |
title_fullStr | A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study |
title_full_unstemmed | A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study |
title_short | A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study |
title_sort | modified regimen of 21-day nab-paclitaxel plus gemcitabine in locally advanced or metastatic pancreatic cancer: a retrospective real-world study |
topic | Hope In Despair - New Progress in The Diagnosis and Treatment of Pancreatic Cancer Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703471/ https://www.ncbi.nlm.nih.gov/pubmed/36423238 http://dx.doi.org/10.1177/10732748221141233 |
work_keys_str_mv | AT changchen amodifiedregimenof21daynabpaclitaxelplusgemcitabineinlocallyadvancedormetastaticpancreaticcanceraretrospectiverealworldstudy AT menglingwei amodifiedregimenof21daynabpaclitaxelplusgemcitabineinlocallyadvancedormetastaticpancreaticcanceraretrospectiverealworldstudy AT lixiaofen amodifiedregimenof21daynabpaclitaxelplusgemcitabineinlocallyadvancedormetastaticpancreaticcanceraretrospectiverealworldstudy AT chengke amodifiedregimenof21daynabpaclitaxelplusgemcitabineinlocallyadvancedormetastaticpancreaticcanceraretrospectiverealworldstudy AT yicheng amodifiedregimenof21daynabpaclitaxelplusgemcitabineinlocallyadvancedormetastaticpancreaticcanceraretrospectiverealworldstudy AT pengbing amodifiedregimenof21daynabpaclitaxelplusgemcitabineinlocallyadvancedormetastaticpancreaticcanceraretrospectiverealworldstudy AT maji amodifiedregimenof21daynabpaclitaxelplusgemcitabineinlocallyadvancedormetastaticpancreaticcanceraretrospectiverealworldstudy AT caodan amodifiedregimenof21daynabpaclitaxelplusgemcitabineinlocallyadvancedormetastaticpancreaticcanceraretrospectiverealworldstudy AT changchen modifiedregimenof21daynabpaclitaxelplusgemcitabineinlocallyadvancedormetastaticpancreaticcanceraretrospectiverealworldstudy AT menglingwei modifiedregimenof21daynabpaclitaxelplusgemcitabineinlocallyadvancedormetastaticpancreaticcanceraretrospectiverealworldstudy AT lixiaofen modifiedregimenof21daynabpaclitaxelplusgemcitabineinlocallyadvancedormetastaticpancreaticcanceraretrospectiverealworldstudy AT chengke modifiedregimenof21daynabpaclitaxelplusgemcitabineinlocallyadvancedormetastaticpancreaticcanceraretrospectiverealworldstudy AT yicheng modifiedregimenof21daynabpaclitaxelplusgemcitabineinlocallyadvancedormetastaticpancreaticcanceraretrospectiverealworldstudy AT pengbing modifiedregimenof21daynabpaclitaxelplusgemcitabineinlocallyadvancedormetastaticpancreaticcanceraretrospectiverealworldstudy AT maji modifiedregimenof21daynabpaclitaxelplusgemcitabineinlocallyadvancedormetastaticpancreaticcanceraretrospectiverealworldstudy AT caodan modifiedregimenof21daynabpaclitaxelplusgemcitabineinlocallyadvancedormetastaticpancreaticcanceraretrospectiverealworldstudy |